Anti-viral activity of thiazole derivatives: an updated patent review

References

• Coronavirus disease (COVID-2019) situation reports, nd. www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (cited 2020 Aug 9). Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers
   Google Scholar
• Mermer A, Keles T, Sirin Y. Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: a review. Bioorg Chem 2021;114:105076.
   PubMed Web of Science ®Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766–788.
   PubMed Web of Science ®Google Scholar
• Corman VM, Muth, D, Niemeyer, D, et al. Hosts and Sources of Endemic Human Coronaviruses. . In: Roossinck, MJ, Kielian, M, Mettenleiter, TC. editors, Advances in virus research, vol 100, 2018. 163–188.
   Google Scholar
• Debing Y, Jochmans D, Neyts J. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol. 2013;3(2):217–224.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China 2019. N Engl J Med. 2020;382:727–733.
   PubMed Web of Science ®Google Scholar
• Li X, Wang W, Zhao X, et al. Transmission dynamics and evolutionary history of 2019-nCoV. J Med Virol. 2020;92:501–511.
   PubMed Web of Science ®Google Scholar
• Xiao M, Xu L, Lin D, et al. Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors. Europ J Med Chem. 2021;213:113161.
   PubMed Web of Science ®Google Scholar
• Mitrasinovic PM. Advances in the structure-based design of the influenza A neuraminidase inhibitors, Curr. Drug Targets. 2010;11:315e326.
   Web of Science ®Google Scholar
• Schwerdtfeger SM, Melzig MF. Sialidases in biological systems. Pharmazie. 2010;65(8):551–561.
   PubMed Web of Science ®Google Scholar
• Cox RM, Toots M, Yoon J-J, et al. Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex. J Biol Chem. 2018;293:16761–16777.
   PubMed Web of Science ®Google Scholar
• Shi W, Jiang Z, He H, et al. Discovery of 3,3’-Spiro[Azetidine]-2-oxo-indoline derivatives as fusion inhibitors for treatment of rsv infection. Med Chem Lett. 2018; 9: 94–97.
   Google Scholar
• You CR, Lee, SW, Jang, JW, et al. Update on hepatitis B virus infection. World J Gastroenterol. 2014;20:13293–13305.
   PubMed Web of Science ®Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(Suppl 1):S45–S57.
   PubMed Web of Science ®Google Scholar
• Yee BE, Nguyen NH, Zhang B, et al. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a metaanalysis. BMJ Open Gastroenterol. 2015;2(1):e000049.
   PubMedGoogle Scholar
• Yeh T-K, Kang I-J, Hsu T-A, et al. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. Eur J Med Chem. 2019;167:245–268.
   PubMed Web of Science ®Google Scholar
• Xiao T, Tang JF, Meng G, et al. Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV- 1NNRTIs: design, synthesis and biological activities. Eur J Med Chem. 2020;186:11864.
   Web of Science ®Google Scholar
• Curreli F, Ahmed S, Victor SMB, et al. Preclinical optimization of gp120 entry-antagonists as anti- HIV-1 agents with improved cytotoxicity and ADME properties through rational design, synthesis, and antiviral evaluation. J Med Chem. 2020;63:1724–1749.
   PubMed Web of Science ®Google Scholar
• UNAIDS fact sheet, https://www.unaids.org/en/resources/documents/2020/UNAIDS_FactSheet
   Google Scholar
• Cannalire R, Chan KWK, Burali MS, et al. Pyridobenzothiazolones exert potent anti-dengue activity by hampering multiple functions of NS5 polymerase. Med Chem Lett. 2020;11(5):773–782.
   Google Scholar
• Yasmin F, Yaqub T, Khan I, et al. Antiviral activity of thiazolide derivatives against dengue virus in Huh-7 cell line. J Microbiol. 2018;11(2):e62467/1–e62467/6.
   Web of Science ®Google Scholar
• Arankalle VA, Shrivastava S, Cherian S, et al. Genetic divergence of Chikungunya viruses in India (1963–2006) with special reference to the 2005–2006 explosive epidemic. J Gen Virol. 2007;88:1967–1976.
   PubMed Web of Science ®Google Scholar
• Ivanova L, Rausalu K, Žusinaite E, et al. 1,3-Thiazolbenzamide derivatives as chikungunya virus nsP2 protease inhibitors. ACS Omega. 2021;6:5786–5794.
   PubMed Web of Science ®Google Scholar
• Álvarez DM, Castillo E, Duarte LF, et al. González current antivirals and novel botanical molecules interfering with herpes simplex virus infection. Front Microbiol. 2020;11:139.
   PubMed Web of Science ®Google Scholar
• Lolis MS, Gonzalez L, Cohen PJ, et al. Drug-resistant herpes simplex virus in HIV infected patients. Acta Dermatovenerol Croat. 2016;16:204–208.
   Google Scholar
• Gudmundsson KS, Johns BA, Allen SH. Pyrazolopyridines with potent activity against herpesviruses: effects of C5 substituents on antiviral activity. Bioorg Med Chem Lett. 2008;18:1157–1161.
   PubMed Web of Science ®Google Scholar
• El-Sabbagh OI, Baraka MM, Ibrahim SM, et al. Synthesis and antiviral activity of new pyrazole and thiazole derivatives. Eur J Med Chem. 2009;44:3746–3753.
   PubMed Web of Science ®Google Scholar
• Abdel Latif NA, Abbas EMH, Farghaly TA, et al. Synthesis, characterization, and anticancer screening of some new bithiazole derivatives. Russ J Org Chem. 2020;56:1096–1107.
   Web of Science ®Google Scholar
• Farghaly TA, Abo Alnaja AM, El-Ghamry HA, et al. Synthesis and DNA binding of novel bioactive thiazole derivatives pendent to N-phenylmorpholine moiety. Bioorg Chem. 2020;102:104103.
   PubMed Web of Science ®Google Scholar
• Omar MA, Masaret GS, Abbas EMH, et al. Novel anti-tubercular and antibacterial based benzosuberone-thiazole moieties: synthesis, molecular docking analysis, DNA gyrase supercoiling and ATPase activity. Bioorg Chem. 2020;104:104316.
   PubMed Web of Science ®Google Scholar
• Mahmoud HK, Farghaly TA, Abdulwahab HG, et al. Novel 2-indolinone thiazole hybrids as sunitinib analogues: design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity. Eur J Med Chem. 2020;208:112752.
   PubMed Web of Science ®Google Scholar
• Al-Soliemy AM, Farghaly TA, Abbas EMH, et al. Synthesis of thiazolyl-N-phenylmorpholine derivatives and their biological activities. Med Chem. 2021;17:790–805.
   PubMed Web of Science ®Google Scholar
• Singh IP, Gupta S, Kumar S. Thiazole compounds as antiviral agents: an update. Med Chem. 2020;16:4–23.
   PubMed Web of Science ®Google Scholar
• Petrou A, Fesatidou M, Geronikaki A. Maria fesatidou and athina geronikaki, thiazole ring—A biologically active scaffold, molecules. Molecules (Basel, Switzerland). 2021;26:3166.
   PubMed Web of Science ®Google Scholar
• Aramita D, Sarkar S, Majee A. Recent advances on heterocyclic compounds with antiviral properties. Chem Heterocycl Compd. 2021;57(4):410–416.
   PubMed Web of Science ®Google Scholar
• Sevrioukova IF, Poulos TL. Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues. Biochemistry. 2013;52:4474–4481.
   PubMed Web of Science ®Google Scholar
• Seck I, Nguemo F. Triazole, imidazole, and thiazole-based compounds as potential agents against coronavirus. 2021;Results Chem. 3:100132.
   PubMedGoogle Scholar
• Deeks ED. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014 Feb;74(2):195–206.
   PubMed Web of Science ®Google Scholar
• Jamie DC1, Caroline MP. Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection. Drugs. 2010 October 1;70(14):1885–1915.
   PubMed Web of Science ®Google Scholar
• Chandwani A. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2008;4(5):1023–1033.
   PubMedGoogle Scholar
• Burns CJ, Coburn G, Liu B, et al. Pyrrole-3-carboxamides as hepatitis B capsid assembly modulators and their preparation. PCT Int Appl. 2021;WO 2021119081 A1 20210617.
   Google Scholar
• Guo W, Zhang D, Jin W, et al. HBV inhibitor and use thereof. PCT Int Appl. 2021 . WO 2021093172 A1 20210520.
   Google Scholar
• Rossignol J-F. Antiviral combinations of thiazolide compounds for treating hepatitis B. PCT Int Appl. 2021 . WO 2021016543 A1 20210128.
   Google Scholar
• Qiu Y-L, Peng X, Li W, et al. Pyrrolopyrimidine derivatives as hepatitis B antiviral agents and their preparation. PCT Int Appl. 2021; WO 2020247575 A1 20201210.
   Google Scholar
• Qiu Y-L, Peng X, Gao X, et al. Hepatitis B antiviral agents. PCT Int Appl. 2021;WO 2020247561 A1 20201210.
   Google Scholar
• Ivashchenko AA, Ivashchenko AV, Savchuk NF, et al., Preparation of hepatitis B virus inhibitors (HBV), Russ RU 2736975 C1 20201123, 2020
   Google Scholar
• Bonsmann S, Donald A, Urban A, et al. Preparation of novel indolizine-2-carboxamides active against the hepatitis B virus (HBV. PCT Int Appl. 2020 . WO 2020221824 A1 20201105.
   Google Scholar
• Panarese J, Davis D, Bartlett S, et al. Functionalized heterocycles as antiviral agents and their preparation. PCT Int Appl. 2020 . WO 2020106816 A1 20200528.
   Google Scholar
• De Francesco R, Donnici L, Guidotti L, et al. Preparation of arylaminocarbonyl pyrrolo-fused tricyclic sulfonamides as inhibitors of hepatitis B virus. PCT Int Appl. 2020. WO 2020030781 A1 20200213.
   Google Scholar
• Deng G, Jiang Y, Liu Q, et al. Preparation of dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases. PCT Int Appl. 2020. WO 2020001448 A1 20200102.
   Google Scholar
• Jiang Y, Wan Z-K, Cheung WS, et al. Preparation of dihydropyrimidine derivatives and uses thereof in the treatment of HBV infection or of HBV-induced diseases. PCT Int Appl. 2019;WO 2019214610 A1 20191114.
   Google Scholar
• Qiu Y-L, Kass J, Suh B-C, et al. Hepatitis B antiviral agents. PCT Int Appl. 2019;WO 2019191166 A1 20191003.
   Google Scholar
• Cheng Z, Han X, Wang Y, et al. Preparation of tetrahydropyridopyrimidine derivatives for use as anti-hepatitis b virus agents. PCT Int Appl. 2018;WO 2018083081 A1 20180511.
   Google Scholar
• Turner W, Arnold LD, Li L, et al. Preparation of dibenzo[b,f] [1,4]thiazepinecarboxamides as hepatitis B core protein modulators. PCT Int Appl. 2018;WO 2018053157 A1 20180322.
   Google Scholar
• Qiu Y-L, Cao H, Peng X, et al. Hepatitis B antiviral agents. PCT Int Appl. 2017;WO 2017214395 A1 20171214.
   Google Scholar
• Qiu Y-L, Cao H, Li W, et al. Preparation of dihydropyrimidines as antiviral agents for the treatment of hepatitis B. PCT Int Appl. 2017;WO 2017011552 A1 20170119.
   Google Scholar
• Cheng Z, Wang J, Wang M, et al. Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection. PCT Int. Appl . WO 2018083106 A1 20180511. 2016.
   Google Scholar
• Li X, Zhou K, He H, et al. design, synthesis, and evaluation of tetrahydropyrrolo[1,2- c]pyrimidines as capsid assembly inhibitors for hbv treatment. ACS Med Chem Lett. 2017;8:969–974. https://doi.org/https://doi.org/10.1021/acsmedchemlett.7b00288
   PubMed Web of Science ®Google Scholar
• Apaydin CB, Tansuyu M, Cesur Z, et al. Design, synthesis and anti-influenza virus activity of furan-substituted spirothiazolidinones. Bioorg Chem. 2021;112:104958.
   PubMed Web of Science ®Google Scholar
• Wang W, Lu Y, Tan J. Antiviral compound with substituted thiazole and benzamide structures and its preparation method., Faming Zhuanli Shenqing CN 112707874 A 20210427. 2021.
   Google Scholar
• Remiszewski S, Chiang LW, Murphy EA, et al. Preparation thiazole and isoquinoline derivs. as broad spectrum antiviral agents. PCT Int Appl. 2019 . WO 2019079519 A1 20190425.
   Google Scholar
• Tang C, Ren Q, Yin J, et al. Preparation of 7-(pyrimidin-2-yl)pyrrolo[2,3-b]pyrazine derivatives useful as inhibitors of influenza virus replication. PCT Int Appl. 2018. WO 2018108125 A1 20180621.
   Google Scholar
• Xu K, Li H, Xu Y, et al., Thiazole derivatives as H3N2 virus inhibitors and their preparation, pharmaceutical compositions and use in the treatment of virus infection, Faming Zhuanli Shenqing, CN 107459496 A 20171212, 2017
   Google Scholar
• Jonckers THM, Raboisson PJ-MB, Guillemont JEG, et al. Preparation of indole derivatives for the treatment of influenza virus infection. PCT Int Appl. 2016. WO 2016020526 A1 20160211.
   Google Scholar
• Osman H, Yusufzai SK, Khan MS, et al. New thiazolyl-coumarin hybrids: design, synthesis, characterization, X-ray crystal structure, antibacterial and antiviral evaluation. J Mol Struct. 2018;1166:147e154.
   Web of Science ®Google Scholar
• Lamut A, Gjorgjieva M, Naesens L, et al. Anti-influenza virus activity of benzo[d]thiazoles that target heat shock protein 90. Bioorg Chem. 2020;98:103733.
   PubMed Web of Science ®Google Scholar
• Chen P, Sun X, Chen J. Medicinal application of N-[5-(1,2,4-triazol-1-yl)thiazol-2-yl]fatty acid amide in preparation of influenza virus neuraminidase inhibitor. Faming Zhuanli Shenqing. 2014. CN 103705511 A 20140409
   Google Scholar
• Cihan-Üstünda˘g G, Zopun M, Vanderlinden E, et al. Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones. Bioorg Med Chem. 2020 January 1; 28(1):115130. https://doi.org/https://doi.org/10.1016/j.bmc.2019.115130
   Google Scholar
• Goel OP. 5-Substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents. U.S: U.S 2020 ; US 10646477 B1 20200512.
   Google Scholar
• Goel OP. 5-Substituted 2,4-thiazolidinediones (thiohydantoins), pseudothiohydantoins, and propseudothiohydantoins for use as antiviral agents. U.S: U.S 2020 ; US 10646477 B1 20200512.
   Google Scholar
• Kleymann G, Gege C. Preparation of enantiomers of substituted thiazoles as antiviral agent. PCT Int Appl. 2019;WO 2019068817 A1 20190411.
   Google Scholar
• He H, Jiang Z, Shi W, et al. Thiazole derivative and applications thereof. PCT Int Appl. 2018;WO 2018127207 A1 20180712. •• interesting for anti-HIV activity of thiazole derivatives.
   Google Scholar
• Bhusare SR, Kasralikar HM, Deokar SC, et al. Preparation of pyrazolothiazole [3,4-d] hybrids as potential anti HIV-1 NNRT inhibitors. Indian Pat Appl IN. 2020. 202021005494 A 20200313
   Google Scholar
• Curreli F, Ahmed S, Benedict V, et al. Preclinical optimization of gp120 entry-antagonists as anti-HIV-1 agents with improved cytotoxicity and ADME properties through rational design, synthesis, and antiviral evaluation. J Med Chem. 2020;63(4):1724–1749.
   PubMed Web of Science ®Google Scholar
• Liotta DC, Jecs E, Altas TY, et al. SC, piperizine derivatives as pan-tropic entry inhibitors and their preparation. PCT Int Appl. 2019;WO 2019183133 A1 20190926.
   Google Scholar
• Brizgys G, Canales E, Chou C-H, et al. Preparation of tetrahdryoindazolylacetamidophenylethylpicolinamide derivatives and analogs for use as antiviral agents. PCT Int Appl. 2014. WO 2014134566 A2 20140904.
   Google Scholar
• Curreli F, Ahmed S, Victor SMB, et al. Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors. Bioorg Med Chem. 2021;32:116000.
   PubMed Web of Science ®Google Scholar
• Kasralikar HM, Jadhavar SC, Goswami SV, et al. Design, synthesis and molecular docking of pyrazolo[3,4-d] thiazole hybrids as potential anti-HIV-1 NNRT inhibitors. Bioorg Chem. 2019;86:437–444.https://
   PubMed Web of Science ®Google Scholar
• Blaisdell TP, Shook BC, Kim IJ, et al. Azepin-2-one derivatives as RSV inhibitors and their preparation. PCT Int Appl. 2019;WO 2019094920 A1 20190516.
   Google Scholar
• Kim IJ, Panarese J, Blaisdell TP, et al. Yat Sun, Preparation of heterocyclic compounds as RSV inhibitors useful in the treatment of respiratory syncytial virus infections. PCT Int Appl. 2019;A1 20190103. WO 2019006291
   Google Scholar
• By Or YS, Blaisdell TP, Shook BC, et al. Preparation of aryldiazepine derivatives as RSV inhibitors for the treatment and prevention of RSV viral infection. PCT Int Appl. 2018;WO 2018226801 A1 20181213.
   Google Scholar
• Tahri A, Jonckers THM, Raboisson PJ-MB, et al. Novel 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents, U.S. Pat Appl Publ. 2015;US 20150166533 A1 20150618.
   Google Scholar
• Wang G, Beigelman L, Truong A, et al. Preparation of carboxamide derivatives as antiviral compounds. PCT Int Appl. 2015;WO 2015026792 A1 20150226.
   Google Scholar
• By Ng T, Molla M-A, Pilot-Matias TJ, et al. Preparation of thiazoles for treatment of respiratory syncytial viral infection. PCT Int Appl. 2014;WO 2014176268 A1 20141030.
   Google Scholar
• Gursoy E, Dincel ED, Naesens L, et al. Design and synthesis of novel Imidazo[2,1-b]thiazole derivatives as potent antiviral and antimycobacterial agents. Bioorg Chem. 2020;95:103496.
   PubMed Web of Science ®Google Scholar
• Riccio A, Santopolo S, Rossi A, et al., Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergenceCell Mol Life Sci . 2021;79:227. DOI:https://doi.org/10.1007/s00018-022-04246-w.
   Web of Science ®Google Scholar
• Szymaniak A, McGrath K, Yu J, et al. Heterocyclic compounds as antiviral agents and their preparation. PCT Int Appl. 2021;WO 2021066922 A1 20210408.
   Google Scholar
• Pathak AK, Augelli-Szafran CE, Ahmed SK, et al., 4-Substituted-2-thiazole amides as antiviral agents and their preparation, U.S. Pat. Appl. Publ., US 20200399264 A1 20201224, 2020
   Google Scholar
• Yang S, Wang T, Zhou Y, et al. Discovery of cysteine and its derivatives as novel antiviral and antifungal agents. Molecules. 2021;26(2):383.
   Web of Science ®Google Scholar
• Glenn JS, Smith M, Pham EA, et al. Preparation of substituted amino-phenylthiazoles and related heterocycles as PI4-kinase inhibitors useful as antiviral and anti-infective agents. PCT Int Appl. 2020;WO 2020191205 A1 20200924.
   Google Scholar
• Glenn JS, Gelman MA, Tavshanjian B, et al. PI4-kinase inhibitors with anti-infective activity, U.S. Pat Appl Publ. 2016;US 20160194314 A1 20160707. ••interesting for Anti-HCV of thiazoles
   Google Scholar
• Zhang Y, Shen C, Li J, et al. Preparation of hepatitis C virus (HCV) inhibitors. Faming Zhuanli Shenqing. 2019; CN 104860931 A 20150826, 2015.
   Google Scholar
• Dockendorff C, Youngsaye W, Nag PP, et al. Preparation of thiazole-based inhibitors of scavenger receptor BI. PCT Int Appl. 2014;WO 2014063167 A1 20140424.
   Google Scholar
• Basyouni WM, Abbas SY, El-Bayouki KAM, et al. Synthesis and antiviral screening of 2-(propylthio)-7-substituted-thiazolo[5,4-d]pyrimidines as anti-bovine viral diarrhea virus agents. J Heterocycl Chem. 2021;58:1766–1774.
   Web of Science ®Google Scholar
• Manvar D, Küçükgüzel I, Erensoy G, et al. Discovery of conjugated thiazolidinone-thiadiazole scaffold as anti-dengue virus polymerase inhibitors. Biochem Biophys Res Commun. 2016;469:743–747.
   PubMed Web of Science ®Google Scholar
• Li S, Xiao J, Xu L, et al. 4-Oxo-4,5-dihydrothiazole derivative, preparation method and use thereof. PCT Int Appl. 2017;WO 2017088776 A1 20170601.
   Google Scholar
• Pacca CC, Marques RE, Espindola JWP, et al. Thiosemicarbazones and Phthalyl-Thiazoles compounds exert antiviral activity against yellow fever virus and Saint Louis encephalitis virus. Biomed Pharmacother. 2017;87:381–387.
   PubMed Web of Science ®Google Scholar
• Sokolova AS, Yarovaya OI, Bormotov NI, et al. Synthesis and antiviral activity of camphor-based 1,3-thiazolidin-4-one and thiazole derivatives as orthopoxvirus-reproduction inhibitors. Medchemcomm. 2018;9:1746–1753.
   PubMed Web of Science ®Google Scholar
• Gürsoy E, Dincel ED, Naesens L, et al. Design and synthesis of novel Imidazo[2,1-b]thiazole derivatives as potent antiviral and antimycobacterial agents. Bioorg Chem. 2020;95:103496.
   PubMed Web of Science ®Google Scholar
• Asraf MA, Hossen MF, Bitu NA, et al. Antiviral compounds: a road to quest for novel antiviral drugs. Ann Med Chem. 2020;1(1):1004.
   Google Scholar
• Andersen PI, Ianevski A, Lysvand H, et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Inter J Infect Dis. 2020;93:268–276.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. J Hepatol. 2009;49:S174–S84.
   Google Scholar
• Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31(1):111–116.
   PubMedGoogle Scholar
• Wiehe A, Brien JMO, Senge MO. Trends and targets in antiviral phototherapy. Photochem Photobiol Sci. 2019;18(11):2565.
   PubMed Web of Science ®Google Scholar
• Ewers EC, Shah PA, Carmichael MG, et al. In concurrent systemic chemo immunotherapy and sofosbuvir-based antiviral treatment in a hepatitis C virus-infected patient with diffuse large B-cell lymphoma. Open Forum Infect Dis. 2016;3(4):ofw223.
   PubMedGoogle Scholar
• Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237–S244.
   PubMed Web of Science ®Google Scholar
• Hanson KE, Swaminathan S. Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management. Future Microbiol. 2015;10(10):1545–1548.
   PubMed Web of Science ®Google Scholar
• Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014;312(6):593–594.
   PubMed Web of Science ®Google Scholar
• Wu D, Wu T, Liu Q, et al. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis. 2020May;94:44–48.
   PubMed Web of Science ®Google Scholar
• Chiamenti L, da Silva FP, Schallemberger K, et al. Cytotoxicity and antiviral activity evaluation of cymbopogon spp hydroethanolic extracts. Braz J Pharm Sci. 2019;55:e18063.
   Web of Science ®Google Scholar
• Nishimura Y, Hara H. Editorial: drug repositioning: current advances and future perspectives. Front Pharmacol. 2018;9:1068.
   PubMed Web of Science ®Google Scholar
• Pizzorno A, Padey B, Terrier O, et al. Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy. Front Immunol. 2019 March 19; 10:531. doi: 0.3389/fimmu.2019.00531.
   PubMed Web of Science ®Google Scholar
• Jan WD, Jeonc S, Kim S, et al. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Pnas. 2021;118(30):e2024302118.
   PubMed Web of Science ®Google Scholar
• Sultana J, Crisafulli S, Gabbay F, et al. Challenges for drug repurposing in the COVID-19 pandemic era. Front Pharmacol. 2020;11:588654.
   PubMed Web of Science ®Google Scholar
• Chakravarty K, Antontsev VG, Khotimchenko M, et al. Accelerated repurposing and drug development of pulmonary hypertension therapies for COVID-19 treatment using an ai-integrated biosimulation platform. Molecules. 2021;26(1912):1912. https://doi.org/https://doi.org/10.3390/molecules26071912
   PubMedGoogle Scholar